1. 1386PDIMpower150: Clinical safety, tolerability and immune-related adverse events in a phase III study of atezolizumab (atezo) + chemotherapy (chemo) ± bevacizumab (bev) vs chemo + bev in 1L nonsquamous NSCLC. (23rd October 2018) Authors: Reck, M; Wehler, T; Orlandi, F; Nogami, N; Barone, C; Moro-Sibilot, D; Shtivelband, M; González Larriba, J L; Rothenstein, J; Frueh, M; Shankar, G; Lee, A; Deng, Y; Patel, H; Kelsch, C; Lin, W; Socinski, M A Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 1817TiPSAKK 17/16 - Lurbinectedin monotherapy in patients with progressive malignant pleural mesothelioma: A multicenter, single-arm phase II trial. (23rd October 2018) Authors: Metaxas, Y; Xyrafas, A; Mark, M T; Pless, M; Frueh, M; Froesch, P R; Schneider, M; Biaggi Rudolf, C; Grosso, F; von Moos, R Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗